
Expert Statement: Vivi Hollertt, Nouryon
The European Chemical Industry has set out on an ambitious path to become carbon neutral.
The European Chemical Industry has set out on an ambitious path to become carbon neutral.
The European Chemical Industry has set out on an ambitious path to become carbon neutral.
The European Chemical Industry has set out on an ambitious path to become carbon neutral.
The European Chemical Industry has set out on an ambitious path to become carbon neutral.
The European Chemical Industry has set out on an ambitious path to become carbon neutral.
The European Chemical Industry has set out on an ambitious path to become carbon neutral.
The European Chemical Industry has set out on an ambitious path to become carbon neutral.
The European Chemical Industry has set out on an ambitious path to become carbon neutral.
The European Chemical Industry has set out on an ambitious path to become carbon neutral.
The European Chemical Industry has set out on an ambitious path to become carbon neutral.
The European Chemical Industry has set out on an ambitious path to become carbon neutral.
The European Chemical Industry has set out on an ambitious path to become carbon neutral.
The European Chemical Industry has set out on an ambitious path to become carbon neutral.
The European Chemical Industry has set out on an ambitious path to become carbon neutral.
The European Chemical Industry has set out on an ambitious path to become carbon neutral.
The European Chemical Industry has set out on an ambitious path to become carbon neutral.
The European Chemical Industry has set out on an ambitious path to become carbon neutral.
The European Chemical Industry has set out on an ambitious path to become carbon neutral.
Digital twin systems transform business by accelerating holistic understanding, optimal decision-making, and effective action.
Alexis Pey, Global SHE & Process Safety Manager at Dutch holding Stahl, talks about the company’s safety culture involving the whole organization.
Hafnium Labs is tackling one of the toughest challenges in chemical R&D: Obtaining reliable physical property data — fast.
BASF has created ZoomLab, a virtual formulation prediction and optimization tool, to help address the challenges of drug product development.
On Dec. 31, 2020, the UK will leave the EU single market and customs union. Regardless of any agreement reached with the EU, the end of the Brexit transition period will affect citizens, businesses, as well as travel between the UK and EU. Therefore, businesses need to prepare themselves for the upcoming changes.
Sean Diver, president of DCAT speaks about the pharmaceutical industry’s role during the Covid-19 pandemic, trends in drug manufacturing, and key issues for the EU pharmaceutical industry.
The coronavirus crisis caused by the Covid-19 pandemic has uncovered problems that have been smoldering beneath the surface of the pharmaceutical industry — including CMOs/CDMOs and CROs — and need to be addressed. That supply chains are vulnerable to disruption when major development, production and transportation hubs are blocked or shut down has become painfully obvious.
So far, the pharmaceutical industry — including CMOs/CDMOs and CROs — has responded well to the outbreak of the Covid-19 pandemic. However, the coronavirus crisis has uncovered problems that have been smoldering beneath the surface and need to be addressed. That supply chains are vulnerable to disruption when major development, production and transportation hubs are blocked or shut down has become painfully obvious.
So far, the pharmaceutical industry — including CMOs/CDMOs and CROs — has responded well to the outbreak of the Covid-19 pandemic. However, the coronavirus crisis has uncovered problems that have been smoldering beneath the surface and need to be addressed. That supply chains are vulnerable to disruption when major development, production and transportation hubs are blocked or shut down has become painfully obvious.
So far, the pharmaceutical industry — including CMOs/CDMOs and CROs — has responded well to the outbreak of the Covid-19 pandemic. However, the coronavirus crisis has uncovered problems that have been smoldering beneath the surface and need to be addressed. That supply chains are vulnerable to disruption when major development, production and transportation hubs are blocked or shut down has become painfully obvious.
So far, the pharmaceutical industry — including CMOs/CDMOs and CROs — has responded well to the outbreak of the Covid-19 pandemic. However, the coronavirus crisis has uncovered problems that have been smoldering beneath the surface and need to be addressed. That supply chains are vulnerable to disruption when major development, production and transportation hubs are blocked or shut down has become painfully obvious.
So far, the pharmaceutical industry — including CMOs/CDMOs and CROs — has responded well to the outbreak of the Covid-19 pandemic. However, the coronavirus crisis has uncovered problems that have been smoldering beneath the surface and need to be addressed. That supply chains are vulnerable to disruption when major development, production and transportation hubs are blocked or shut down has become painfully obvious.
So far, the pharmaceutical industry — including CMOs/CDMOs and CROs — has responded well to the outbreak of the Covid-19 pandemic. However, the coronavirus crisis has uncovered problems that have been smoldering beneath the surface and need to be addressed. That supply chains are vulnerable to disruption when major development, production and transportation hubs are blocked or shut down has become painfully obvious.
So far, the pharmaceutical industry — including CMOs/CDMOs and CROs — has responded well to the outbreak of the Covid-19 pandemic. However, the coronavirus crisis has uncovered problems that have been smoldering beneath the surface and need to be addressed. That supply chains are vulnerable to disruption when major development, production and transportation hubs are blocked or shut down has become painfully obvious.
So far, the pharmaceutical industry — including CMOs/CDMOs and CROs — has responded well to the outbreak of the Covid-19 pandemic. However, the coronavirus crisis has uncovered problems that have been smoldering beneath the surface and need to be addressed. That supply chains are vulnerable to disruption when major development, production and transportation hubs are blocked or shut down has become painfully obvious.
So far, the pharmaceutical industry — including CMOs/CDMOs and CROs — has responded well to the outbreak of the Covid-19 pandemic. However, the coronavirus crisis has uncovered problems that have been smoldering beneath the surface and need to be addressed. That supply chains are vulnerable to disruption when major development, production and transportation hubs are blocked or shut down has become painfully obvious.
So far, the pharmaceutical industry — including CMOs/CDMOs and CROs — has responded well to the outbreak of the Covid-19 pandemic. However, the coronavirus crisis has uncovered problems that have been smoldering beneath the surface and need to be addressed. That supply chains are vulnerable to disruption when major development, production and transportation hubs are blocked or shut down has become painfully obvious.